Arvinas, Inc.

Arvinas, Inc.

Arvinas, Inc.

Overview
Date Founded

2013

Headquarters

5 Science Park,395 Winchester Avenue,New Haven, CT 06511

Type of Company

Public

Employees (Worldwide)

67

Industries

Biotechnology

Company Description

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Executives & Employees

Chief Executive Officer, President & Director

Executive Director-Corporate Counsel

Chief Financial Officer

Manager

Manager

Manager

Manager

Board of Directors

General Partner at Canaan Management, Inc.

Member (Attorney) at Epstein Becker & Green PC

Executive Partner at Mpm Capital LLC

Managing Partner at 5AM Venture Management LLC

Chief Executive Officer at Cerevance LLC

Chief Executive Officer, President & Director at Arvinas, Inc.

Manager at Arvinas, Inc.

Manager at Arvinas, Inc.

Paths to Arvinas, Inc.
Potential Connections via
Relationship Science
You
Arvinas, Inc.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

New Leaf Ventures Partners focuses exclusively in healthcare companies located in the US with strong management teams and revenues exceeding $100 million. They targets companies operating in the fields of biopharmaceutical, information convergence (HCIT), medical device and life science tools.The firm provides financing for early and later stage capital requirements and invests in both public & private companies.

Details Hidden

Deerfield Management Co. focuses on investments in growth stocks across the healthcare sector. They target companies with sound fundamentals, long-term earnings growth potential and the potential to capitalize on market trends. Deerfield's approach is based on extensive fundamental research into healthcare sector assets and investment opportunities. They invest mainly in US companies or companies that issue securities available in US public markets. Although this is their focus, there is no geographic limitation on investments and Deerfield may invest outside the US when situations warrant. Their funds generally pursue one of 3 strategies: Large-Cap, Special Situations and Private Design.Deerfield's Large-Cap strategy invests mainly in debt and equity securities, including exchange traded derivative securities, of publicly-traded companies in the healthcare sector. The strategy seeks capital appreciation through a combination of security selection based on fundamental analysis, diversification through investments in stock, debt and derivatives and a mix of long and short positions.The firm's Special Situations strategy emphasizes investments in publicly traded healthcare companies with smaller market-caps. At least 90% of investments must in healthcare companies, and essentially all investments are healthcare related. Investments include equity, debt, royalties or other assets, some of which may have limited liquidity. The strategy makes both long and short investments and may utilize leverage.Deerfield's Private Design strategy invests in public and private healthcare companies using privately created instruments, structures and transactions. This may include, but is not limited to, joint ventures, project financing, contracting for revenue streams, purchasing products/services outright (including intellectual property), participating in LBOs, restructurings and outright buyouts, and developing/participating in the development and sale of therapeutics, medical devices and healthcare products/services.

Recent Transactions
Details Hidden

Arvinas, Inc. issued USD Common Stock

Details Hidden

Arvinas, Inc. raised money in a private placement transaction

Details Hidden

Arvinas, Inc. raised money in a private placement transaction

Transaction Advisors
Underwriter

Advised onArvinas, Inc. issued USD Common Stock

Escrow Agent

Advised onArvinas, Inc. issued USD Common Stock

Auditor

Advised onArvinas, Inc. issued USD Common Stock

Legal Advisor

Advised onArvinas, Inc. issued USD Common Stock

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of 2017
Market Capitalization
$692M
Total Enterprise Value
Earnings Per Share
$-0.89
Revenue
$7.58M
Net Profit
$-24M
EBITDA
$-24.4M
EBITDAMargin
-322.12%
Total Debt
$310K
Total Equity
$246K
Investors
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

New Leaf Ventures Partners focuses exclusively in healthcare companies located in the US with strong management teams and revenues exceeding $100 million. They targets companies operating in the fields of biopharmaceutical, information convergence (HCIT), medical device and life science tools.The firm provides financing for early and later stage capital requirements and invests in both public & private companies.

Details Hidden

Deerfield Management Co. LP (Private Equity) invests in a broad range of industries. It provides financing for buyout transactions to private and public companies located in the U.S.

Suppliers
Yale University Internet Software & Services | New Haven, CT

Yale University is an American private Ivy League research university located in New Haven, Connecticut. Founded in 1701 in the Colony of Connecticut, the university is the third-oldest institution of higher education in the United States.

Competitors
Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Middlesex

GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products. It operates through the following segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

C4 Therapeutics, Inc. Biotechnology - Watertown, MA

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in 2015 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Arvinas, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Arvinas, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Arvinas, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/arvinas-inc-178931714
  • https://relationshipscience.com/organization/arvinas-inc-178931714